Financial OutlookThe analyst maintains a BUY rating for Envoy Medical, raising the 12-month price target to $9.00, representing significant upside from the current share price.
Market OpportunityEnvoy Medical's Acclaim CI, a fully implanted cochlear implant, addresses a significant market opportunity by eliminating the need for an external component.
Regulatory ProgressThe recent IDE approval for the Acclaim CI with the FDA to begin clinical testing is a significant milestone for the company.